Geron Corp (NASDAQ:GERN) reported four presentations linked to imetelstat at the 59th ASH Annual Meeting held in Atlanta, Georgia. Imetelstat marks as a telomerase inhibitor preliminary advanced by company and solely licensed to Janssen Biotech, Inc. on a worldwide basis. The presentations can be accessed on Geron’s website.
John A. Scarlett, M.D., the CEO and President of Geron, reported that they and their associate are delighted to record this initial presentation of report from IMerge exhibiting an eight-week transfusion independence rate of 54% among the subjects who were naïve to HMAs and lenalidomide and who didn’t have del(5q), which indicates that imetelstat could provide lower risk MDS subjects a much-required treatment alternative.
Besides, the non-clinical report presentations continue to facilitate the prospective application of imetelstat in numerous hematologic malignancies. They continue to be thrilled by the consistent interest in imetelstat by several collaborators across the globe.
Geron reported that the poster presentation described report from the first 32 subjects registered in Part I of IMerge, the underway Phase 2/3 clinical study of imetelstat in red blood cell transfusion-dependent subjects with lower risk MDS. Transfusion Dependent is stated as an RBC transfusion need of ≥4 units over eight weeks prior to moving into the study.
The primary efficacy objective is the rate of RBC TI lasting minimum 8 weeks, stated as the proportion of subjects in absence of any RBC transfusion during any successive eight weeks since moving to the study. Key secondary objectives are the rate of HI-E and the rate of 24-week TI, defined as an increase in hemoglobin of minimum 1.5 g/dL above the pretreatment mark for at least eight weeks or a decline of at least four units of RBC transfusions over eight weeks against the previous RBC transfusion burden.
In the last trading session, the stock price of Geron gained more than 1% to close the day at $2.